The global oral cancer rapid test kit market is anticipated to grow at a considerable CAGR of 4.9% during the forecast period (2023-2030). The major factor that drives market growth includes the increasing incidence of oral cancer and growing awareness about oral cancer and its early detection methods. According to the American Cancer Society, about 54,540 new cases of oral cavity or oropharyngeal cancer were recorded in the US, and 11,580 deaths were recorded from oral cavity or oropharyngeal cancer in 2022. Moreover, technological advancements in oral cancer diagnosis and treatment procedures, are a factor that boosts the market growth. For instance, in April 2023, the University of Surrey (Guildford, UK) developed PANDORA, a proof-of-concept test that demonstrated over 92% accuracy in identifying patients with OSCC and over 80% accuracy in detecting pre-cancer or OED. The study involved taking cell samples from a test group of 40 people with Oral squamous cell carcinoma (OSCC) and Oral epithelial dysplasia (OED,) as well as 79 people without cancer, including those with other benign lesions.
Browse the full report description of “Oral Cancer Rapid Test Kit Market Size, Share & Trends Analysis Report by Type (Onc Alert Oral Cancer LAB, Lab on Chip, Insilixa Test, and Prevo-Check) and by Application (Hospitals, Diagnostic Center, and Research Centers) Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/oral-cancer-rapid-test-kit-market
In March 2022, Researchers at Queen Mary University of London developed a PCR test for mouth cancer. The test has now been proved with patients from China, India, and the UK, with the results published in the international journal, Cancers. A tiny sample (the size of half a grain of rice) is taken from the suspicious area in the patient’s mouth and the test only takes 90 minutes for detecting the result.
In August 2022, OrisDX developed a novel saliva-based molecular test to detect and diagnose oral cancer earlier—improving patient outcomes and saving lives. Using biomarker-based molecular genomic techniques to diagnose oral cavity cancers earlier, OrisDX’s technology is based on the latest science and has been proven in clinical studies.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Type
o By Application
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- including Abbott Laboratories, Becton, Dickinson and Company, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., GRAIL, LLC, and others
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Oral Cancer Rapid Test Kit Market Report Segment
By Type
By Application
Global Oral Cancer Rapid Test Kit Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/oral-cancer-rapid-test-kit-market